-
Prensa Medica Argentina Jul 1963
Topics: Breast Diseases; Cysts; Humans; Lymphadenitis; Mastodynia; Neurotic Disorders; Norethindrone; Norsteroids; Pain
PubMed: 14090064
DOI: No ID Found -
Journal of Obstetrics and Gynaecology... Oct 2022Tamoxifen is prescribed for chronic mastalgia at a dosage of one 10- or 20-mg tablet for 3-6 months. A topical preparation of this drug has recently been approved. The... (Meta-Analysis)
Meta-Analysis Review
OBJECTIVES
Tamoxifen is prescribed for chronic mastalgia at a dosage of one 10- or 20-mg tablet for 3-6 months. A topical preparation of this drug has recently been approved. The aim of this study was to meta-analyze the effectiveness of tamoxifen and its different regimens for the treatment of mastalgia. We also sought to summarize the side effects and the follow-up results of these treatments.
DATA SOURCES
We searched the databases of PubMed/ MEDLINE, Central, Embase, and EBSCO from August 2021 to September 2021.
STUDY SELECTION
Articles on the effects of tamoxifen in mastalgia were searched, and randomized controlled trials were retrieved for inclusion in this study. PRISMA guidelines were followed, and we selected 9 articles for the meta-analysis.
DATA EXTRACTION AND SYNTHESIS
A proforma was prepared for data collection. RevMan 5.4 software was used for methodological quality assessment, statistical analysis, and preparation of forest plots. Oral tamoxifen performed better than placebo (risk ratio [RR] 2.04; 95% CI 1.49-2.78, P < 0.001). No significant difference in efficacy was seen between the 10- and 20-mg dosages (RR 1.08; 95% CI 0.97-1.21, P = 0.18) when used for 3 months.
CONCLUSION
Oral tamoxifen is helpful in long-standing mastalgia. It is safe and effective at an oral dose of 10 mg.
Topics: Humans; Mastodynia; Randomized Controlled Trials as Topic; Tamoxifen
PubMed: 35752405
DOI: 10.1016/j.jogc.2022.06.006 -
American Journal of Surgery Dec 1981Nineteen patients were evaluated for breast pain and nodularity associated with fibrocystic disease. Rapid pain relief occurred in 73 of patients, with total relief in...
Nineteen patients were evaluated for breast pain and nodularity associated with fibrocystic disease. Rapid pain relief occurred in 73 of patients, with total relief in 47 percent after daily treatment with 0.1 mg of levothyroxine. Softening of breast tissue and decreased nodularity occurred within 3 months in many patients. Three patients had elevated levels of serum prolactin before treatment, with dramatic pain relief and normalization of prolactin levels after treatment. Further trials of levothyroxine in patients with mastodynia due to fibrocystic disease appear justified.
Topics: Adult; Breast Diseases; Female; Fibrocystic Breast Disease; Humans; Pain; Prolactin; Thyroxine
PubMed: 7316045
DOI: 10.1016/0002-9610(81)90330-5 -
Gynecological Endocrinology : the... Nov 2022Dysmenorrhea and mastodynia are the most common gynecologic pain causes in women of all ages and races during their reproductive life. The following study aimed to show...
INTRODUCTION
Dysmenorrhea and mastodynia are the most common gynecologic pain causes in women of all ages and races during their reproductive life. The following study aimed to show the influence of two POP´s in the development of dysmenorrhea and mastodynia after nine months of use.
MATERIAL AND METHODS
A total of 858 women with 6691 drospirenone (DRSP) cycles and 332 women with 2487 desogestrel (DSG) cycles were analyzed. Women included in this study were all child-bearing potentials, at risk of pregnancy, agreeing to use only the study medication for contraception for the duration of the study medication treatment, aged 18 to 45.
RESULTS
At screening, 168 (19.6%) of the 858 patients using DRSP and 64 (19,3%) of the DSG patients reported that they had suffered from dysmenorrhea within six cycles prior to the first visit before starting with the medication. 20,2% of the DRSP and 10,9% of the DSG group had a sever dysmenorrhea. After 9 cycles this was reduced to 0,6% and 3,1% respectively. In total, 96 women (11.2%) in the DRSP and 49 (14,8%) experienced mastodynia within six cycles before the screening. Of these 91.6% in the DRSP group and 91,8% in the DSG group had no or mild mastodynoa at follow-up.
DISCUSSION
The progestins 4 mg and desogestrel 0,075 mg showed a marked effect in the non-contraceptive aspects of dysmenorrhea and mastodynia so that new possibilities are opened for these two benign gynecological diseases. Future studies must reaffirm these first data.
Topics: Pregnancy; Female; Humans; Desogestrel; Progestins; Dysmenorrhea; Mastodynia; Progesterone Congeners; Ethinyl Estradiol; Contraceptives, Oral, Combined
PubMed: 36265507
DOI: 10.1080/09513590.2022.2134339 -
The Surgical Clinics of North America Apr 2013This article presents an overview of the benign conditions that affect the breast for the practicing surgeon. The authors discuss the diagnosis and management of a... (Review)
Review
This article presents an overview of the benign conditions that affect the breast for the practicing surgeon. The authors discuss the diagnosis and management of a variety of breast pathologic conditions, including those associated with infection and inflammation as well as proliferative and nonproliferative disorders. The authors also offer their experience with the integration of nurse practitioners in the care of patients with benign breast disease.
Topics: Abscess; Breast; Breast Diseases; Breast Neoplasms; Fat Necrosis; Female; Fibroadenoma; Humans; Hyperplasia; Lymphedema; Mastodynia; Nurse Practitioners; Papilloma; Sclerosis
PubMed: 23464687
DOI: 10.1016/j.suc.2013.01.001 -
Journal de Gynecologie, Obstetrique Et... Dec 2015To evaluate the diagnostic value of clinical examination and additional tests in the exploration of breast pain, to evaluate the strategy of their care and to provide... (Review)
Review
OBJECTIVES
To evaluate the diagnostic value of clinical examination and additional tests in the exploration of breast pain, to evaluate the strategy of their care and to provide recommendations.
METHODS
A literature search in English and French carried out by consulting the databases PubMed, Cochrane Library and international recommendations.
RESULTS
Clinical examination and interrogation, with the use of visual analog scale used to differentiate non-cyclical breast pain from mastodynia (LE2). A calendar can be used to characterize the cyclical breast pain (LE3). Using a questionnaire can help to characterize the pain (LE3). In the absence of palpable abnormality, it is not recommended to modify systematic or individual screening modalities (LE2). MRI is not recommended in case of normal mammography and sonography. Explorations biopsy is guided by imaging. The therapeutic management includes reassurance after a normal clinical evaluation and/or normal radiological findings (LE2), and precise fitting of a brassière. In case of failure of this first approach, NSAIDs gel can be proposed (LE1-2).
Topics: Breast Diseases; Female; Humans; Mastodynia; Practice Guidelines as Topic
PubMed: 26541567
DOI: 10.1016/j.jgyn.2015.09.039 -
BMJ Clinical Evidence Jan 2011Breast pain may be cyclical (worse before a period) or non-cyclical, originating from the breast or the chest wall, and occurs at some time in 70% of women. Cyclical... (Review)
Review
INTRODUCTION
Breast pain may be cyclical (worse before a period) or non-cyclical, originating from the breast or the chest wall, and occurs at some time in 70% of women. Cyclical breast pain resolves spontaneously in 20% to 30% of women, but tends to recur in 60% of women. Non-cyclical pain responds poorly to treatment but tends to resolve spontaneously in half of women.
METHODS AND OUTCOMES
We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments for breast pain? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS
We found 24 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS
In this systematic review we present information relating to the effectiveness and safety of the following interventions: antibiotics, bromocriptine, combined oral contraceptive pill, danazol, diuretics, evening primrose oil, gestrinone, gonadorelin analogues, hormone replacement therapy (HRT), lisuride, low-fat diet, progestogens, pyridoxine, tamoxifen, tibolone, topical or oral non-steroidal anti-inflammatory drugs (NSAIDs), toremifene, and vitamin E.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Breast Diseases; Evidence-Based Medicine; Humans; Mastodynia; Pain; Pain Measurement; Toremifene; Treatment Outcome
PubMed: 21477394
DOI: No ID Found -
Acta Obstetricia Et Gynecologica... 1985A 54-year-old postmenopausal woman is described who quite suddenly experienced intense tenderness and tension in both breasts lasting for about 3 weeks. Subsequently she...
A 54-year-old postmenopausal woman is described who quite suddenly experienced intense tenderness and tension in both breasts lasting for about 3 weeks. Subsequently she had a uterine bleeding. Excessively increased levels of estradiol (peak value 2325 pmol/l) were found during the period of mastodynia. Seven months previous to this event, hyperthyroidism had been diagnosed. She had, however, been treated with propylthiouracil and was euthyroid long before and during the period of mastodynia.
Topics: Breast; Estradiol; Female; Humans; Menopause; Middle Aged; Pain; Uterine Hemorrhage
PubMed: 4061070
DOI: 10.3109/00016348509156738 -
Plastic and Reconstructive Surgery Sep 2005Mastodynia is among the most frequently reported symptoms in women with breast complaints; it is usually classified as cyclic, noncyclic, or nonbreast in origin. A...
BACKGROUND
Mastodynia is among the most frequently reported symptoms in women with breast complaints; it is usually classified as cyclic, noncyclic, or nonbreast in origin. A useful response with medical or conservative therapy is obtained in the majority of these patients. There is a subset of patients, however, who have exhausted every medical effort and psychiatric counseling and will desire mastectomy with breast reconstruction in the hope of alleviating their chronic pain.
METHODS
Three patients with noncyclical, bilateral mastodynia referred for breast reconstruction options from December of 2000 to March of 2004 are presented in this article. Daily breast pain charts with a visual analogue scale for pain assessment were analyzed and recorded for all patients throughout the study period.
RESULTS
Two patients underwent delayed reconstruction and had complete resolution of pain 6 to 8 weeks after bilateral mastectomy, with no recurrence of mastalgia after reconstruction. One patient underwent bilateral mastectomy with immediate reconstruction and achieved complete resolution of her pain 3 months postoperatively. Histopathologic findings of all breast specimens revealed benign breast tissue with proliferative breast disease consistent with mastodynia.
CONCLUSIONS
This modality, which includes mastectomy with or without reconstruction, is a viable alternative after exhaustion of all other nonsurgical options and when quality of life is significantly affected. Although mastectomy for the treatment of mastodynia refractory to medical therapy does not guarantee alleviation of chronic breast pain, it should be considered in these often desperate patients.
Topics: Adult; Breast Diseases; Chronic Disease; Female; Humans; Mammaplasty; Mastectomy; Middle Aged; Pain; Quality of Life; Retrospective Studies
PubMed: 16163081
DOI: 10.1097/01.prs.0000178073.63595.a2 -
Praxis 2017
Topics: Breast Diseases; Breast Neoplasms; Diagnosis, Differential; Female; Humans; Mastodynia; Menstrual Cycle; Pain Management; Precision Medicine; Remission, Spontaneous
PubMed: 28976254
DOI: 10.1024/1661-8157/a002795